MRNA - Moderna Inc - Cost Indicator - Financial Analysis - iStock

COST ANALYSIS - Recent 8 Quarters

Numbers in millions	Revenue	Research And Developemnt Expense	Selling and Administrative Expense	Research And Developemnt Expense To Revenue	Selling and Administrative Expense To Revenue
2024-06	240	1221	N/A	506.64%	N/A
2024-03	167	1063	N/A	636.52%	N/A
2023-06	344	1148	N/A	333.72%	N/A
2023-03	1863	1131	N/A	60.7%	N/A

COST ANALYSIS - Recent 5 Years

Numbers in millions	Revenue	Research And Developemnt Expense	Selling and Administrative Expense	Research And Developemnt Expense To Revenue	Selling and Administrative Expense To Revenue
2023-12	6847	4845	N/A	70.75%	N/A
2022-12	19262	3295	N/A	17.11%	N/A
2022-09	12120	3295	N/A	27.19%	N/A
2021-12	18471	1991	567	10.78%	3.07%
2020-12	803	1370	188	170.57%	23.4%

People Also Ask

pfizer financial ratios mrna financial statement mrna stock moderna financial report moderna financial ratios mrna vaccine moderna debt to equity ratio mrna stock news

Financial Analysis Related Information

Moderna Financial Ratios for Analysis 2016-2022 | MRNA

Moderna Financial Ratios for Analysis 2016-2022 | MRNA ; Current Ratio. 1.7606. 1.435 ; Long-term Debt / Capital. 0.0406. 0.0412 ; Debt/Equity Ratio. 0.0423. 0.043.

Moderna Inc. (NASDAQ:MRNA) | Financial Analysis and Stock ...

An approach to decomposing Moderna Inc. return on equity, return on assets, and net profit margin ratio as the product of other financial ratios.

MRNA | Moderna Inc. Financial Statements - WSJ

Moderna Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View MRNA financial statements in full.

Moderna Inc (MRNA) Financial Ratios - Investing.com

MRNA Ratios · P/E Ratio TTM, 3.32 Price to Sales TTM, 2.03 · Gross margin TTM, 71.71% Gross Margin 5YA, - · Revenue/Share TTM, - Basic EPS ANN · Return on Equity ...

Moderna Inc (MRNA) Financial Summary - Investing.com India

MRNA Financial Summary ; Gross margin TTM, 71.71% ; Operating margin TTM, 68.02% ; Net Profit margin TTM, 61.12% ; Return on Investment TTM, 101.58% ...

Moderna Inc, MRNA:NSQ summary - FT.com - Markets data

As of last trade Moderna Inc (MRNA:NSQ) traded at 121.60, 5.72% above its 52-week low of 115.03, set on Sep 29, 2022. 52-week range. Today. 115.03Sep 29 2022 ...

Moderna, Inc. (MRNA) Stock Price Today, Quote & News

MRNA Moderna, Inc. Stock Price & Overview ; Valuation · P/E Non-GAAP (FWD). 4.78. P/E GAAP (TTM). 3.82. Price/Book (TTM) ; Growth · Revenue (YoY). 227.61%. Revenue ...

Moderna Inc. Annual Income Statement - MRNA - MarketWatch

Moderna Inc. Annual stock financials by MarketWatch. View the latest MRNA financial statements, income statements and financial ratios.

Disclaimer

All the information on the website is for reference only. If the user trades according to this information, he/she shall be responsible for any transaction loss. This website is not responsible for any errors in the content of the information or delay in updating.